0      0

JL1122ES - JL1122ES: Maintained ECOG-PS with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase III SUNLIGHT trial

‐ Oct 24, 2023 4:00pm

Full author listing:

Julien Taieb, MD, PhD (1), Gerald W. Prager, MD, PhD (2), Marwan Fakih, MD (3), Fortunato Ciardiello, MD, PhD (4), Eric Van Cutsem, MD, PhD (5), Elena Elez, MD, PhD (6), Felipe Melo Cruz, PhD (7), Lucjan Wyrwicz, MD, PhD (8), Daniil Stroyakovskiy, MD, PhD (9), Zsuzsanna Pápai, PhD (10), Pierre-Guillaume Poureau, MD (11), Gabor Liposits, MD, PhD (12), Chiara Cremolini, MD, PhD (13), Igor Bondarenko, MD, PhD (14), Dominik Paul Modest, MD (15), Nadia Amellal, MD (16), Hasnaa Hassan,MS, PharmD (16), Donia Skanji, PhD (16), Josep Tabernero, MD, PhD (6)

1) Université Paris-Cité, (Paris Descartes), Georges Pompidou European Hospital, SIRIC CARPEM, Paris, France. 2) Medical University Vienna, Vienna, Austria. 3) City of Hope Comprehensive Cancer Center, Duarte, USA. 4) Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy. 5) University Hospitals Leuven and KU Leuven, Herent, Belgium. 6) Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain. 7) Núcleo de Pesquisa e Ensino da Rede São Camilo, Sao Paulo, Brazil. 8) Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, Poland. 9) Moscow City Oncological Hospital #62, Moscow, Russian Federation. 10) Duna Medical Centre, Budapest, Hungary. 11I) nstitut de Cancérologie, Brest, France. 12) University of Southern Denmark, Odense, Denmark. 13) University of Pisa, Pisa, Italy. 14) Dnipropetrovsk Medical Academy, Dnipro, Ukraine. 15) Charité Universitätsmedizin, Berlin, Germany. 16) Servier International Research Institute, Suresnes, France.


You must be logged in and own this session in order to post comments.